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Damage-associated molecular patterns (DAMPs) include endogenous intracellular molecules released by activated or necrotic
cells and extracellular matrix (ECM) molecules that are upregulated upon injury or degraded following tissue damage. DAMPs
are vital danger signals that alert our immune system to tissue damage upon both infectious and sterile insult. DAMP activation
of Toll-like receptors (TLRs) induces inﬂammatory gene expression to mediate tissue repair. However, DAMPs have also been
implicated in diseases where excessive inﬂammation plays a key role in pathogenesis, including rheumatoid arthritis (RA), cancer,
and atherosclerosis. TLR activation by DAMPs may initiate positive feedback loops where increasing tissue damage perpetuates
pro-inﬂammatory responses leading to chronic inﬂammation. Here we explore the current knowledge about distinct signalling
cascades resulting from self TLR activation. We also discuss the involvement of endogenous TLR activators in disease and highlight
how speciﬁcally targeting DAMPs may yield therapies that do not globally suppress the immune system.
1. The Danger Hypothesis
Both infection and sterile tissue injury generate strong
immune responses. This paradox was ﬁrst resolved by
Matzinger in 1994 who proposed that our immune system is
designed to combat danger, rather than mediate recognition
of non-self over self [1]. Pathogen-associated molecular
patterns (PAMPs) and endogenous molecules created upon
tissue injury, since called damage-associated molecular pat-
terns (DAMPs), signal the threat of either infection or
injury to the organism, independently of their non-self- or
self-identity [2–5]. Among the cellular receptors that sense
these danger signals, Toll-like receptors (TLRs) represent
a key molecular link between tissue injury, infection, and
inﬂammation. In the last decade a number of endogenous
molecules speciﬁcally generated upon tissue injury that
activate TLRs have been identiﬁed. Some are intracellular
molecules normally inaccessible to the immune system
that are released into the extracellular milieu as a result
of cell necrosis or activation following injury. Others are
extracellular matrix (ECM) molecule fragments that are
released upon tissue damage or ECM molecules that are
speciﬁcally upregulated in response to tissue injury [6].
In addition to playing a key role in host defence against
danger, activation of TLRs has been linked to the patho-
genesis of many inﬂammatory and autoimmune diseases
including sepsis, rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE), inﬂammatory bowel disease (IBD),
type I diabetes, and multiple sclerosis (MS). Hence, in
recent years TLRs and associated signalling molecules have
become attractive targets for their treatment and a number
ofinhibitorsarecurrentlyindevelopmentorhaveprogressed
to clinical trials. Aberrant TLR activation is also thought
to contribute to diseases with a strong association with
inﬂammation such as cancer and atherosclerosis (reviewed
in [7–11]).
One of the key questions to emerge from these studies
is what factors drive TLR activation during the progression
of disease. There is an increasing body of evidence to
suggest that DAMP-mediated inﬂammation plays a vital
role. It is also becoming apparent that PAMPs and DAMPs
act in quite a diﬀerent manner in order to stimulate an
immune response. Here we review the mechanisms of
DAMP recognition by TLRs, the signalling cascades, and
the biological outcomes resulting from self TLR activation,
focusing on the diﬀerences to non-self TLR activation.2 Mediators of Inﬂammation
We also discuss the evidence that implicates endogenous
molecules in pathological TLR activation and examine how
blockade of DAMP action may be therapeutically beneﬁcial.
Understanding more about the diﬀerences between PAMP-
and DAMP-induced inﬂammation may enable us to specif-
ically target inappropriate, pathogenic inﬂammation whilst
leaving the host defence intact.
2. Endogenous Activatorsof TLRs
The ﬁrst report of a putative endogenous activator of TLRs
dates back to 2000, when heat shock protein 60 (HSP60) was
shown to induce cytokine synthesis through TLR4 activation
[12]. In the same year necrotic cells were found to induce
pro-inﬂammatory and tissue repair gene synthesis and cause
DC maturation in a TLR2 dependent manner, as a result
of the release of their intracellular contents [13, 14]. The
list of endogenous TLR2 and 4 activators has expanded
quickly and encompasses other intracellular molecules such
as heat shock proteins including HSP70, Gp96 [15–17],
HSP22, and HSP72 [18, 19] and high-mobility group box-1
protein (HMGB1) [20–22]a sw e l la sE C Mm o l e c u l e ss u c ha s
biglycan [23], tenascin-C [24], versican [25], and fragments
of ECM molecules including oligosaccharides of hyaluronic
acid (HA) [26] and heparan sulfate (HS) [27].
Notably, the list of TLRs activated by endogenous
molecules is also expanding. For instance, TLR1 was shown
for the ﬁrst time to be required, along with TLR2, for
the activation of professional antigen-presenting cells by β-
defensin-3, a host-derived antimicrobial peptide [28]. Self-
nucleic acids have also been described as endogenous danger
signals, namely, mRNA recognised by TLR3 [29], single-
stranded RNA (ssRNA) sensed by TLR7 and 8 [30], and IgG-
chromatincomplexesrecognisedbyTLR9[31].Interestingly,
emerging data support the activation of TLR7 and 8 by
antiphospholipid antibodies (APL) isolated from patients
with APL syndrome [32, 33], as has been also shown
previously for TLR2 and 4 [34–36]. A more complete list of
DAMPs and their cognate TLRs can be found in Figure 1.
Given the use of E. coli to produce many of these
endogenous molecules recombinantly, and the fact that
most endogenous proteins activate TLR2 and 4, origi-
nally described as sensors of microbial products such as
lipopolysaccharides (LPSs) and lipoproteins, the question
of whether microbial contamination can partially or wholly
account for DAMP activity remains a key issue. Erridge and
Samani recently showed that apparent stimulation of TLR4
by saturated fatty acids was due to microbial contamination
in their preparations of BSA [37]. In contrast, professional
antigen-presenting cells that are not responsive to LPS were
shown to be activated by necrotic cells indicating that LPS
independent TLR4 activation does occur in response to
endogenous ligands [38]. Similar to TLR2, TLR3 was also
shown to recognize cells undergoing necrosis during acute
inﬂammatory events, independently of viral infection [39].
Indeed, as details of the mechanisms of endogenous TLR
ligand recognition emerge, it becomes clear that there are
signiﬁcant diﬀerences between PAMP and DAMP activation
of TLRs. We discuss these diﬀerences in detail in the
following sections of this review. In addition, the phenotype
of mice with targeted deletions in a number of endogenous
TLR activators conﬁrms that removal of endogenous danger
signals correlates with the eﬀects of addition of exogenous
DAMPs. Together these data indicate that DAMP activity is
not reliant on the presence of contaminating PAMPs.
Recent data indicate that endogenous danger signals and
microbial products can also cooperate in the induction of
immune responses. Neither highly puriﬁed HSP prepara-
tionsnorLPSaloneatconcentrationscorrespondingtothose
found in contaminated HSP preparations could induce pro-
inﬂammatory cytokine production (reviewed in [40–42]).
Further studies showed that HSP60 and Gp96 can tightly
bind to LPS in a saturable manner and enhance its biological
a c t i v i t y ,a sw e l la st h a to ft h eT L R 2l i g a n dP a m 3Cys [43–
45]. In the light of these results, the function of HSPs
has been proposed to modulate early immune responses
during infection by mediating a synergy between PAMPs
and DAMPs. Similarly, HSP90 has also been implicated in
the recognition of CpG DNA by TLR9 and the binding of
HMGBs to nucleic acids is required for eﬃcient recognition
by TLR3, 7, and 9 [46–48].
3. Mechanisms of TLR Activation by
DAMPs versus PAMPs
There is an increasing body of evidence that demonstrates
how exogenous and endogenous activation of TLRs is
mediatedandthisrevealsthat,whilstthereissomeoverlapin
molecular machinery, DAMPs possess distinct mechanisms
of action to PAMPs. These similarities and diﬀerences
emerge below where we explore the mechanisms of PAMP
and DAMP recognition by TLRs and the subsequent TLR
signalling and biological outcomes.
3.1. Ligand Recognition by TLRs
3.1.1. Exogenous Ligand Recognition. TLRs interact with a
wide variety of ligands ranging from proteins and lipopro-
teins to nucleic acids and saccharides, all of which are
diﬀerent in size and chemical properties. The extracellular
domains (ECDs) of TLRs contain leucine-rich repeat (LRR)
motifs that are responsible for PAMP recognition [49].
The crystal structures of three TLR ECD-ligand complexes
have been solved. One structure shows that TLR3 interacts
withhydrophilicdouble-strandedRNA(dsRNA)viasurface-
exposed sites [50]. A second structure shows TLR1-TLR2
heterodimers bound to the hydrophobic Pam3CSK4 lipopep-
tide that ﬁts in an internal hydrophobic pocket [51]. Finally,
the structure of the TLR4-MD-2-LPS complex shows that
TLR4 employs the co-receptor MD-2 to recognise LPS and
that no direct contacts between the receptor and the ligand
takeplace[52–54].Thelatterstructurealsoprovidedinsights
into the structure-activity relationship of the lipid A moiety
of LPS. Not only the number of lipid chains [55, 56]b u t
also the phosphate groups and their positioning in the lipid
Aa r ei m p o r t a n tf a c t o r sa ﬀecting the immunological activityMediators of Inﬂammation 3
Proteins, peptides
TLR1 β-defensin-3 [28]
TLR2 HSP60, 70, Gp96 [15, 17, 74]
HMGB1 [20-22]
HMGB1-nucleosome complexes [89]
β-defensin-3 [28]
Surfactant protein A, D [73, 79]
Eosinophil-derived neurotoxin [209] 
Antiphospholipid antibodies [34]
TLR4 HMGB1 [20-22]
Fibronectin EDA [81]
Fibrinogen [200]
Tenascin-C (FBG) [24]
Surfactant protein A, D [78, 79]
β-defensin-2 [204]
HSP60, 70, 72, 22, Gp96 [12, 15-19, 74]
S100A8 (MRP8) [120, 143]
S100A9 (MRP14) [120, 143]
Neutrophil elastase [205]
Antiphospholipid antibodies [35, 36]
Lactoferrin [80]
TLR7 Antiphospholipid antibodies [32]
Proteoglycans, glycosaminoglycans
TLR2
TLR4
Biglycan [23]
Versican [25]
Hyaluronic acid fragments [26]
Biglycan [23]
Heparan sulfate fragments [27]
Hyaluronic acid fragments [26]
Nucleic acids, protein-nucleic acids
complexes
TLR3
TLR7
mRNA [29]
ssRNA [30]
Fatty acids, lipoproteins
TLR2
TLR4
Serum amyloid A [201, 203]
Serum amyloid A [202, 169]
Oxidised LDL [206, 76, 207]
Saturated fatty acids [82, 208]
TLR8 ssRNA [30]
TLR9 IgG-chromatin complexes [31]
TLR8 Antiphospholipid antibodies [32, 33]
Figure 1: Endogenous TLR activators. TLRs are activated by damage-associated molecular patterns (DAMPs) including intracellular
molecules released in the extracellular milieu by activated or necrotic cells and extracellular matrix molecules either upregulated upon
injury or degraded following tissue damage. Known endogenous TLR activators are listed based on their biochemical nature.
of LPS [53]. This suggests that even minor modiﬁcations to
ligands may cause signiﬁcant changes in the responses they
generate.
These three crystal structures highlight three diverse
modes of exogenous ligand recognition by TLRs involving
TLR homo- and heterodimerization as well as direct TLR-
ligand interactions or the use of co-receptors and accessory
molecules. A number of accessory molecules have been
shown to assist microbial recognition by TLRs. For instance,
LPS is extracted from the bacterial membrane by the LPS-
binding protein (LBP) after which it is transferred to
CD14. Subsequent transfer from CD14 to an additional
accessory molecule MD-2 then allows TLR4-mediated LPS
recognition [57]. Interestingly, in the absence of MD-2,
the LPS-dependent TLR4 signalling can be reconstituted by
the mite dust allergen Der p 2, which has structural and
functional homology with MD-2 and mimics the activity of
MD-2 by presenting LPS to TLR4 [58, 59]. HMGB1 can also
mediate LPS transfer to CD14 to initiate a TLR4-mediated
pro-inﬂammatory response [60]. In B cells, the TLR-like
molecule radioprotective 105 (RP105) forms a complex with
the MD-2 homolog MD-1 and is essential for regulating
TLR2 and 4-dependent antibody production to the ligands
lipoproteins and LPS. Conversely, in macrophages and
DCs, RP105/MD-1 acts as a TLR4 decoy receptor that,
by interacting directly with the TLR4 signalling complex,
inhibits the ability of the receptor to bind microbial ligands
[61, 62]. Other accessory molecules bind directly to TLR
ligands. CD14 facilitates LPS transfer to TLR4/MD-2 and,
accordingly, in the absence of CD14 rough LPS cannot
initiate the TRIF/TRAM pathway and smooth LPS cannot
be detected at all [63, 64]. CD14 binds also to triacylated
lipopeptides facilitating their recognition by TLR2/TLR1
complexes [65] and can enhance dsRNA-mediated TLR3
activation [66]. CD36 is a sensor of diacylated lipopep-
tides recognised by TLR2/TLR6 [67]. NAD(P)H oxidase 4
(Nox4) modulates the production of LPS-induced reactive
oxygen species (ROS) by interacting with the cytoplasmic
TIR domain of TLR4 [68, 69]. TLRs also cooperate with
other families of receptors to recognise microbial ligands.
TLR2 was shown to collaborate with dectin-1 in zymosan
recognition [70] or with the macrophage receptor with
collagenous structure (MARCO) in addition to CD14 to
respond to TDM, a cell wall glycolipid from Mycobacterium
tuberculosis [71]. Collectively these data point to speciﬁc
and complex mechanisms at the basis of PAMP recognition,
highlighted by the requirement of a number of distinct co-
receptors and accessory molecules for individual ligands.4 Mediators of Inﬂammation
3.1.2. Endogenous Ligand Recognition by TLRs. No crystal
structures of TLR-endogenous ligand complexes have been
reported so far. Most of the proposed endogenous TLR
activators have been shown to form complexes with TLRs in
vitrobymeansofimmunoprecipitationassaysandfunctional
cell-basedassaysorinvivo,takingadvantageofmicedeﬁcient
in TLRs or their adaptor proteins. Recently, FRET confocal
microscopy and GFP fragment reconstitution have been
proposed to study TLR interaction and measure distances
between receptors in the range of molecular interactions
[72]. This technique might be of great beneﬁt in demon-
stratingandcharacterisingendogenousligandrecognitionby
TLRs.
There exists circumstantial evidence that DAMPs and
PAMPs may occupy the same or neighbouring binding
sites on TLRs. For instance, surfactant protein A was
shown to downregulate peptidoglycan and zymosan induced
NFκB activation and TNFα secretion by binding to the
extracellular domain of TLR2 in RAW 264.7 and alveolar
macrophages [73, 74]. However, some DAMPs may utilize
diﬀerent binding sites; whilst the TLR4 mutations D299G
and T399I prevent activation by LPS, these polymorphisms
confer enhanced ability of TLR4 to respond to ﬁbrinogen
[75].
There is also evidence that DAMPs require diﬀerent co-
receptors and accessory molecules to PAMPs. Reviewing the
proposed modes of endogenous ligand recognition leads
to a rational classiﬁcation of endogenous molecules based
on the receptor, co-receptor(s), and accessory molecule(s)
requirement for recognition by TLR(s) and subsequent
cellular activation that is summarized in Figure 2.Aﬁ r s t
group of DAMPs requires both CD14 and MD-2. This
includes both TLR2 and 4 agonists, such as HSP60, HSP70,
and biglycan, as well as TLR4 activators such as oxidized
LDL and S100 proteins [15, 23, 69, 76, 77]. A second group
of DAMPs requires only CD14 as an accessory molecule
and these are surfactant protein A and D and lactoferrin
[78–80]. A third group comprises DAMPs that have been
shown to involve only MD-2 in their recognition by TLRs.
Among these, Gp96 and HMGB1 activate TLR2 and 4,
whereas ﬁbronectin EDA (FNEDA) and saturated fatty
acids activate TLR4 [17, 20, 22, 81–86]. A fourth group
includesDAMPsthatuseco-receptorsoraccessorymolecules
diﬀerent from CD14 and MD-2. Biglycan was recently
shown to induce the NLRP3/ASC inﬂammasome through
activation of TLR2/4 and purinergic P2X4/P2X7 receptors
[87]. Versican-induced responses require TLR2, TLR6, and
CD14 [25]. HA dependent TLR4 activation involves CD44
in addition to MD-2 [88]. Autoantibodies against dsDNA
and nucleosomes from SLE patients induce DC activation
through TLR2 if bound to HMGB1 [89, 90]. Similarly,
HMGB1 mediates the activation of plasmacytoid DCs and
B cells through TLR9 by DNA-containing immune com-
plexes through a mechanism involving the immunoglobulin
superfamily member RAGE [46]. IgG2a-chromatin immune
complexes require the synergistic engagement of IgM and
TLR9 to activate B cells [31]. TLR7, 8, and TLR9 expressed
by pDCs respond to self-RNA and -DNA respectively
when coupled with the endogenous antimicrobial peptide
LL37 [91, 92]. Furthermore, CD32 delivers DNA-containing
immune complexes found in serum from SLE patients to
intracellular lysosomes containing TLR9, leading to DC
activation [89, 90]. Finally, B cells are activated by DNA-
or RNA-associated autoantigens by combined B cell antigen
receptor (BCR)/TLR9 or TLR7 engagement [93, 94]. This
is a provisional list of endogenous activators and their
accessory molecules that will certainly expand as we learn
more about DAMP-TLR interactions. Collectively, these data
indicate that several co-receptors and accessory molecules
required for ligand recognition by TLRs are employed by
both DAMPs and PAMPs. Further detailed investigation
of how DAMPs are recognised by the cell is required to
elucidatetheprecisestructuralorganizationofthesereceptor
complexes. A signalling competent conformation of the
receptor is required for TLRs to function; however it is not
known whether the conformation induced by DAMPs is
similar or distinct to that produced by microbial structures
where sequential changes in receptor conformation occur
upon ligand binding (reviewed in [95]).
3.2.TLRSignallingandBiologicalOutcomes. Ligand-induced
receptor homo- or heterodimerization leads the cytoplasmic
signalling domains of TLRs to dimerize. Despite diverse
mechanismsofligandinteraction,PAMP-TLRcomplexcrys-
tal studies showed striking similarities in the organization
of ligand-TLR dimer complexes that may apply to all TLRs.
All three structures feature an “m”-shaped TLR dimeric
architecture in which the C-terminal ends of the TLRs
converge and, presumably, cause dimerization of the intra-
cellular domains for signal initiation (reviewed in [97]). The
resulting TIR-TIR complex initiates downstream signalling
through recruitment of speciﬁc adaptor molecules. Five
adaptors have been described so far: myeloid diﬀerentiation
factor88(MyD88),MyD88-adaptorlike(Mal),TIRdomain-
containing adaptor inducing IFN-beta (TRIF), TRIF-related
adaptor molecule (TRAM), and sterile alpha and HEAT-
Armadillo motifs (SARM) [98].
Depending on the adaptors recruited to the TLRs, two
major intracellular signalling pathways can be activated by
TLRs. The ﬁrst, a MyD88-dependent pathway, is activated by
allTLRsexceptTLR3.ItinvolvestheIL-1R-associatedkinases
(IRAK), IRAK-1 and IRAK-4, TNF receptor-associated fac-
tor 6 (TRAF-6), and mitogen-activated kinases (MAPK) and
it culminates in the activation of the transcription factor
NFκB via the IkB kinase (IKK) complex. In turn, NFκB
mediates the transcription of pro-inﬂammatory cytokine
genes. The second pathway, known as TRIF pathway, is
independent of MyD88 and can be activated upon stimula-
tion of TLR3 or 4. It leads to activation of the interferon-
regulated factors (IRF) family of transcription factors via
recruitment of TRIF and results in the synthesis of interferon
(IFN).
TLR signalling pathways induced by endogenous
molecules in diﬀerent cell types are poorly investigated, but
recent studies report usage of distinct adaptor molecules
and induction of distinct signalling pathways downstream
of TLRs when stimulated with exogenous or endogenousMediators of Inﬂammation 5
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Figure 2: Endogenous ligand recognition by TLRs. The co-receptor(s) and accessory molecule(s) required by DAMPs for recognition by
TLR(s) and subsequent cellular activation are shown. (a) TLRs localised on the plasma membrane; (b) TLRs resident in intracellular
compartments. (∗)HMGB1 may require MD-2 and CD14 for TLR4 activation (see [96]).
molecules. Activation of TLR4 by LPS can induce both
TRIF and MyD88-dependent pathways. In contrast, we have
shown that the endogenous TLR4 agonist tenascin-C signals
viaMyD88[24]. Similarly, biglycan has been shown to signal
through TLR2 and 4 in a MyD88-dependent manner [23].
TLR signalling results in the activation of transcription
factors regulating the expression of speciﬁc genes whose
products trigger various cellular responses. For example,
NFκB, AP-1, and IRF5 control the expression of genes
encoding inﬂammatory cytokines, whereas IRF3 and IRF76 Mediators of Inﬂammation
induce the expression of type I IFN and IFN-inducible
genes. Thus a large number of proteins are synthesised
that mediate inﬂammatory and immune responses and
include inﬂammatory cytokines such as IL-1, IL-6, TNFα,
IL-12, IFNs, chemokines, adhesion molecules, costimulatory
molecules, growth factors, tissue-degrading enzymes such as
metalloproteinases,andenzymesthatgenerateinﬂammatory
mediators such as cyclo-oxygenase 2 and inducible nitric
oxide synthase (iNOS).
Diﬀerent microbial agents trigger multiple pathways in
diﬀerent cell types and induce the expression of distinct
subset of genes [99–103]. A detailed comparative analysis
of the biological outcomes induced by diﬀerent endogenous
versus exogenous TLR molecules has not been performed.
However, some crucial diﬀerences between host responses to
endogenous versus microbial agents are emerging.
HMGB1 and LPS were shown to induce distinct patterns
of gene expression in neutrophils. For instance, expression
of monoamine oxidase B and the anti-apoptosis protein Bcl-
xl was increased in neutrophils by HMGB1 but not by LPS.
Furthermore, whilst the cytokine expression proﬁle induced
by HMGB1 versus LPS was similar, a slower induction of
TNFα mRNA occurred upon LPS stimulation compared to
HMGB1 [20, 104, 105]. HSP60 and LPS, in addition to
synergistically enhancing IL-12p40 and IFNγ production in
murinemacrophagesandinmHSP60-expressingCOS1cells,
were shown to diﬀerentially activate APC function. Indeed,
only HSP60 was able to stimulate the production of IFNα
in peritoneal macrophages and bone marrow-derived DCs
and IFNα release was not further increased by HSP60/LPS
complexes [43]. Hyaluronan fragments generated following
injury were reported to induce inﬂammatory responses
distinct from LPS. A microarray analysis performed on the
mouse alveolar macrophage cell line (MH-S) generated a list
of genes that respond diﬀerently to hyaluronan and LPS.
For instance, MMP13, TGF-β2, SOCS3, and other genes
were induced exclusively by hyaluronan. There were also
major diﬀerences in the cytokine proﬁle induced. While
some cytokines including TNFα, MCP-1, and RANTES
were equally induced by both ligands, others, such as
granulocyte macrophage-colony stimulating factor (GM-
CSF), granulocyte colony-stimulating factor (G-CSF), and
IL-1α, were signiﬁcantly diﬀerent [88]. We have shown that
tenascin-C stimulated pro-inﬂammatory cytokine synthesis
in primary human macrophages and synovial ﬁbroblasts in
a cell type speciﬁc manner, which was signiﬁcantly diﬀerent
from LPS. Tenascin-C dose dependently induced TNFα,I L -
6 ,a n dI L - 8p r o d u c t i o ni nh u m a nm a c r o p h a g e s .H o w e v e r ,i t
only induced IL-6 synthesis in synovial ﬁbroblasts, whereas
LPS induced both IL-6 and IL-8 [24]. Further investigation
is required to fully deﬁne the diﬀerences in signalling
pathwaysandgeneexpressioninducedbyendogenousversus
exogenous TLR activators.
4.DAMPs andDisease
DAMPs are key danger signals that alert the organism
to tissue damage and initiate the process of tissue repair.
However, in addition to this physiological role in the
response to tissue injury, there is evidence which indicates
thatendogenousTLRactivatorsalsocontributetothepatho-
genesisofmanyinﬂammatoryandautoimmunediseasesthat
are characterized by aberrant TLR activation.
4.1. High Levels of DAMPs Are Associated with Human
Inﬂammatory Disease. The etiology of many inﬂammatory
and autoimmune diseases is unclear; the initiating stim-
uli are often not well deﬁned and the reasons why the
mechanisms that ordinarily control the immune response
fail are not known. However, it is clear that these dis-
eases are characterized by an extremely destructive tissue
environment. Accordingly, high levels of DAMPs occur
locally and/or systemically in many of these conditions. For
example,awiderangeofendogenousTLRactivators,includ-
ing heat shock proteins, HMGB1, host DNA, ﬁbrinogen,
FNEDA, and tenascin-C, are observed in synovia of RA
patients but not in synovia from normal joints or non-
inﬂamed synovia from osteoarthritis (OA) patients [106–
112]. High levels of HMGB1 and tenascin-C circulate in
the serum of septic patients [113, 114], and high serum
concentrations of DNA-containing immune complexes are
associated with SLE [46], including nucleosome-HMGB1
complexes [90, 115]. In addition, elevated levels of low
MW HA fragments are reported in the bronchial alveolar
lavage ﬂuid and serum of patients with inﬂammatory lung
diseases [116–118]. In many cases levels of endogenous
TLR activators are indicative of disease activity; elevated
levels of extracellular HMGB1 localize speciﬁcally to active
lesions of multiple sclerosis (MS) patients and correlate
with active inﬂammation [119]. Furthermore, the S100
family of calcium binding proteins have long been reliable
biomarkers of inﬂammation in a wide variety of diseases;
for example, both MRP8 and MRP14 levels in the RA
synovium and synovial ﬂuid correlate with disease activ-
ity to a degree greater than levels of C-reactive protein
(reviewed in [120]). Many endogenous TLR activators are
also overexpressed in tumor cells. Figure 3 summarises some
of the diseases with which endogenous TLR activators are
associated.
4.2. Administration of Exogenous DAMPs Induces Inﬂamma-
tion In Vivo. Further support of a role for endogenous TLR
activators in driving disease derives from in vivo studies
using experimental models of inﬂammatory disease. Levels
of many DAMPs are elevated during the pathogenesis of
numerous diseases in rodent models. In addition, delivery
of exogenous DAMPs promotes inﬂammation in vivo via
activation of TLRs. Intra-articular injection of the TLR4
activators FNEDA or tenascin-C induces joint inﬂammation
in wild type but not in TLR4 null mice [24, 86]. Systemic
injection of HS causes lethal sepsis, similar to that induced
by LPS or zymosan, in wild type but not in TLR4 null mice
[121].Furthermore,DNAreleasedfromnecrotichepatocytes
stimulates cytokine synthesis via activation of TLR9 during
murine acetaminophen-induced liver injury [122]. These
a n do t h e rs t u d i e sa r es u m m a r i z e di nTable 1. In addition,Mediators of Inﬂammation 7
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disease [265, 266] 
￿ Lupus [267] 
￿ Psoriasis [268]  
￿ Rheumatoid arthritis [269-271] 
￿ Sepsis [140]  
￿ Systemic sclerosis [120]
￿ Tumors inc breast, lung,      
pancreatic, colorectal,  
[120]
SA100A8/A9
Low MW HA
￿ Rheumatoid arthritis [251] 
￿ Sarcoidosis [116, 117] 
￿ Systemic sclerosis [252] 
￿ Tumors inc pancreatic [253]  Tenascin-C
￿ Atherosclerosis [272] 
￿ Asthma [273, 274] 
￿ Diabetes [275, 276] 
￿ Inflammatory bowel 
disease [277]
￿ Infection [278, 279] 
￿ Multiple sclerosis [280] 
￿ Rheumatoid arthritis 
[108, 281, 282]
￿ Sepsis [113]   
￿ Tumors inc brain, breast,
lung, liver, skin, prostate,
kidney, bladder,    
lymphoma, ovarian [283]  
Versican
￿ Atherosclerosis [284] 
￿ Multiple sclerosis [211] 
￿ Tumors inc bone, lung [285]  
HSPs
￿ Atherosclerosis [240, 241] 
￿ Diabetes [236] 
￿ Inflammatory bowel  
disease [242] 
￿ Lupus [243] 
￿ Multiple sclerosis [244-246]
￿ Psoriasis [247]  
￿ Rheumatoid arthritis [109] 
￿ Sepsis [248] 
￿ Tumors inc breast, lung 
[249, 250]
Fibrinogen
￿ Atherosclerosis [219, 220] 
￿ Multiple sclerosis [221] 
￿ Rheumatoid arthritis [106] 
￿ Sepsis [221] 
￿ Tumors inc breast [222], 
ostesarcoma [223] 
FNEDA
￿ Atherosclerosis [224]  
￿ Psoriasis [225, 226] 
￿ Rheumatoid arthritis [110] 
￿ Sepsis [227] 
￿ Tumors inc liver, lung,    
colon [228, 229] 
Heparan sulfate 
disease [231] 
￿ Lupus [232] 
￿ Tumors inc lung [233],  
colon, bladder, breast [234]  
￿ Atherosclerosis [210, 211]
￿ Tumors inc colorectal [215],  
liver [216], osteosarcoma 
￿ Atherosclerosis [230] 
￿ Inflammatory bowel 
Figure 3: DAMPs and human disease. High levels of many DAMPs are associated with a wide variety of inﬂammatory and autoimmune
diseases as well as with atherosclerosis and cancer.
many DAMPs can act as adjuvants; this has recently been
comprehensively reviewed by Kono and Rock [6]. For
example, puriﬁed genomic dsDNA boosted both antibody
and CD8+ T cell responses in mice when injected with
antigen [123]. Likewise lactoferrin, defensins, low MW HA,
and HMGB1 all exhibit adjuvant properties in vivo [124–
127]. Together these data show that many endogenous TLR
activators exhibit pro-inﬂammatory properties in vivo.
4.3. Inhibition of DAMP Action In Vivo Ameliorates Dis-
ease. Whilst many DAMPs can induce TLR dependent
inﬂammation in vivo, this does not necessarily demonstrate
that these molecules are important in the progression of
disease. This evidence has come from mice that do not
express speciﬁc endogenous TLR activators (Table 2)a n d
studies showing that inhibition of DAMP function can
ameliorate disease in vivo (Table 3) and we review these data
below.
4.3.1.TargetedDeletionofDAMPsProtectsfromInﬂammatory
Disease. Biglycan null mice have a considerable survival
beneﬁt in LPS-induced sepsis due to reduced TLR2 and 4
dependentcytokinesynthesis,cellularinﬁltrationintotissues
[23], and lower levels of active caspase-1 and mature IL-1β
in the kidney, lung, and circulation [87]. We have shown
that tenascin-C null mice are protected from persistent joint
inﬂammationandtissuedestructionduringantigen-induced
arthritis [24]. In addition, mice lacking MRP8/MRP14 com-
plexes are protected from endotoxin-induced lethal shock
and E. coli-induced abdominal sepsis [140, 143] and exhibit
reduced lesion volume, brain swelling, and inﬂammatory
cellinﬁltrationduringcerebralischemia[142].Furthermore,
consistentwiththeirenhancedexpressionduring myocardial
infarction, mice that lack MRP-8/14 complexes exhibited
reduced inﬂammatory cell inﬁltration upon experimental
arterial injury and attenuated atherosclerotic lesions and
macrophage accumulation in plaques compared with mice
deﬁcient in apolipoprotein E alone [141].8 Mediators of Inﬂammation
Table 1: DAMPs induce disease in vivo. Administration of DAMPs to rodents either intra-articularly (i.a.), intracerebroventricularly (i.c.),
intraperitoneally (i.p.), intratracheally (i.t.), or intravenously (i.v.) can provoke pathological inﬂammation in vivo.
Pathology DAMP Eﬀect Refs
Atherosclerosis Apo CIII-rich VLDL (i.v.) Stimulated TLR2 dependent monocyte
activation and adhesion
[128]
Brain injury HMGB1 (i.c.)
Increased cytokines, taste aversion,
fever, mechanical allodynia, promotes
severity of infarction
[129–131]
Gut inﬂammation HMGB1 (B box) (i.p.)
Increased ileal mucosal permeability
and bacterial translocation to
mesenteric lymph nodes
[132]
Joint disease
FNEDA (i.a.)
Induced TLR4 dependent transient
ankle swelling, cytokine synthesis,
synovial inﬂammation
[86]
HMGB1 (i.a.) Induced synovial inﬂammation, some
pannus formation
[133]
Tenascin-C (i.a.) Induced TLR4 dependent joint
inﬂammation and tissue erosion
[24]
Liver injury DNA
During acetaminophen induced cell
death induced TLR9 dependent tissue
injury
[134]
HMGB-1 (i.p.) Aggravated ischemic reperfusion
injury
[135]
Lung injury HMGB-1 (i.t.)
Stimulated acute inﬂammatory injury,
neutrophil accumulation, edema,
cytokine production
[136–138]
Sepsis HS (i.p.) Induced TLR4 dependent lethality [121]
HMGB1 (i.p.) Induced partially TLR4 dependent
lethality
[114]
Table 2:T argeteddeletiono fD AMP spr otectsfr omexperimentaldisease.MicewhichdonotexpresscertainDAMPsexhibitreducedsymptoms
of inﬂammatory disease or tumor metastasis in vivo.
DAMP Disease Model Eﬀe c to fd e l e t i o n Refs
Biglycan
Renal inﬂammation (unilateral
ureteral obstruction) Reduced kidney damage [87]
Sepsis (LPS or zymosan) Protected from lethality [23, 87]
FNEDA Atherosclerosis (Apo E deﬁcient,
high fat diet)
Reduced lesion size, number and
macrophage inﬁltration
[139]
MRP8/MRP14
Abdominal sepsis (E. coli) Reduced bacterial dissemination,
systemic inﬂammation, liver damage
[140]
Arterial injury (femoral wire
insertion)
Reduced inﬂammatory cell inﬁltration
and neotintimal formation
[141]
Atherosclerosis (Apo E deﬁcient,
high fat diet)
Attenuated atherosclerotic lesions and
macrophage accumulation in plaques
[141]
Cerebral ischemia (cerebral
artery occlusion)
Reduced lesion volume, brain swelling
and inﬂammatory cell inﬁltration
[142]
Lethal sepsis (LPS ) Protects from lethality [143]
Vasculitis (cytokine induced) Reduced neutrophil accumulation and
lesion severity
[141]
Tenascin-C
Destructive joint inﬂammation
(antigen induced arthritis)
Protected from joint erosion and tissue
destruction
[24]
Tumorigenesis (cross with
MMTV/PyV mice) Induced smaller tumor nests [144]Mediators of Inﬂammation 9
Table 3: Manipulation of DAMP function ameliorates experimental disease. Therapeutic blockade of DAMP function, for example, using
monoclonal or polyclonal antibodies (mAb, pAb) or speciﬁc inhibitors or silencing DAMP expression by siRNA can reduce disease
progression in vivo.
DAMP Disease Model Mechanism of blockade Refs
HA
Lung inﬂammation
(bleomycin)
Over expression of HA synthase improved
survival and decreased apoptosis
[145]
Sepsis (LPS) High MW HA reduced lung neutrophil
inﬁltration and cytokine synthesis
[146]
HMGB1
Brain injury (transient
ischemia)
mAb reduced infarct size and severity,
locomotor function, cytokine synthesis
[130]
Colitis (DSS, TNBS)
pAb, ethyl pyruvate ameliorated disease,
reduced cytokine synthesis, associated
tumors
[147, 148]
Lung inﬂammation (LPS) pAb decreased neutrophils, lung edema [136, 138]
Lung injury (ventilator) Ab improved oxygenation, neutrophil inﬂux,
cytokine synthesis
[149]
Hepatic ischemia
reperfusion injury pAb decreased liver damage [135]
Acute pancreatitis (duodenal
loop closure)
pAb improved pancreas and lung damage,
aggravated bacterial translocation to pancreas
[150]
Hemorrhagic shock (blood
withdrawal)
pAb improved survival, ameliorated ileal
permeability, decreased serum cytokines
[151]
Hemorrhagic lung injury
(cyclo-phosphamide)
pAb reduced pulmonary edema, neutrophil
accumulation, lung permeability
[152]
Sepsis (LPS, E. Coli,c e c a l
ligation and puncture)
pAb, mAb, DNA binding box A protected
from/reversed lethality, rescues taste aversion
[114, 129, 153–155]
Ethyl pyruvate, stearoyl
lysophosphatidylcholine, nicotine (inhibit
secretion) protected from lethality
[156–158]
Neural ant-inﬂammatory peptides vasoactive
intestinal peptide and urocortin rescue
lethality
[159]
Cisplatin (nuclear sequestration of HMGB1)
protected from lethality
[160]
Rheumatoid arthritis
(Collagen)
pAb, DNA binding box A reduced severity of
established joint disease
[161]
HSP90
Rheumatoid arthritis
(Collagen, adjuvant)
SNX-7081 (inhibitor) ameliorated disease,
joints returned to normal
[162]
Tumorigenesis (nude mice) BX-2819 (inhibitor) inhibited tumor growth [163]
Neutrophil elastase
Acute lung injury (LPS
induced)
Sivelestat or L-658,758 (inhibitors) reduced
HMGB levels and lung damage
[164, 165]
Colitis (dextran) ONO-5046 (inhibitor) reduced disease
severity
[166]
Rheumatoid arthritis
(Collagen)
ONO-5046 (inhibitor) reduced incidence
and severity of disease, ablated cartilage
destruction
[167]
Hepatic ischemia
reperfusion injury
GW311616A (inhibitor) ameliorated liver
damage, decreased neutrophil inﬁltration
[168]
Serum amyloid A Tumorigenesis (LLC
inoculation) pAb reduced lung metastasis [169]
Versican Tumorigenesis (LLC
inoculation) siRNA reduced lung metastasis [25]10 Mediators of Inﬂammation
4.3.2. DAMP Antagonists Ameliorate Disease. The fact that
blockade of DAMP function ameliorates disease in vivo
further supports a role for endogenous TLR activators in
inﬂammatory disease. The best example of how this can be
achieved is with HMGB1 (reviewed in [170–174]), although
manipulation of other DAMPs including HA, neutrophil
elastase (NE), and versican can all protect against disease
(Table 3) .D A M P sc o m p r i s ea ne n o r m o u s l yd i v e r s es u b s e t
of molecules. As such there exists a number of diﬀerent
mechanisms to prevent their inﬂammatory action, some of
which are described below.
(i) Blockade of TLR Activation. One strategy that has
proved eﬀective is to manipulate the function of individual
DAMPs by preventing TLR activation at the cell surface.
Administration of polyclonal anti-HMGB1 antibodies or the
DNA-binding A box of HMGB1, a competitive inhibitor
of the pro-inﬂammatory B box, can reverse the lethality of
established sepsis [114, 153, 154] and ameliorate collagen-
induced arthritis in rodents (reviewed in [161]). However,
whilst some reports demonstrate that monoclonal anti-
HMGB1 antibodies are eﬃcacious preventing organ damage
in experimental models of sepsis [155], others suggest
that monoclonal antibodies are not eﬀective in suppressing
arthritic disease in vivo [175]. This may be due to the
multivalent nature of the mode of action of HMGB1.
One alternative approach may be to use synthetic, bent
oligonucleotides that have a high aﬃnity for HMGB1, and
suppress HMGB1-induced proliferation and migration of
smooth muscle cells in vitro [176]. Another approach may
be the use of an engineered mutant fragment, HMGB1 Mut
(102–105) carrying two glycine substitutions, that decreased
TNFα release induced by the full-length HMGB1 protein in
humanmonocytecultures[177].Inaddition,theN-terminal
domain of thrombomodulin, an endothelial anticoagulant
cofactor,exertsanti-inﬂammatoryeﬀectsin amodeloflethal
endotoxemia partly by binding to and sequestering HMGB1
[178].
(ii) Prevention of DAMP Accumulation. DAMPs can be gen-
erated by release from necrotic cells, secretion from activated
cells, cleavage of larger molecules, or speciﬁc upregulation
upon tissue injury. Manipulation of tissue levels of DAMPs
may provide another window of therapeutic opportunity.
Indeed, ethyl pyruvate, stearoyl lysophosphatidylcholine,
and nicotine have been shown to be eﬃcacious in ameliorat-
ingexperimentalsepsisbypreventingHMGB1releaseduring
experimental sepsis [156–158]. However, the mechanism by
which they do so is unclear and these compounds are likely
also to aﬀect numerous other cell processes. HMGB1 is
released from cells by two distinct mechanisms: it is liberated
from cells undergoing necrosis [179], or it is hyperacetylated
and then actively secreted from stimulated cells. This non-
classical secretion pathway is distinct from the passage
through the ER and Golgi taken by signal tagged proteins,
instead requiring the microtubule cytoskeleton [180]. Other
DAMPs including the S100 proteins are also secreted in
the same way [181] and targeting this pathway therefore
may potentially oﬀer a means to modulate the release of
intracellular DAMPs.
One class of DAMPs comprises ECM fragments gener-
atedbyreleasefromintactmatrices.Inhibitionofthisprocess
has been demonstrated; for example, release of immune-
stimulatory HS fragments from the ECM in vivo can be
mediatedbytheproteolyticactionofelastase[182].Injection
of elastase into the peritoneal cavity of mice caused the
releaseofHSandinducedsepsis,nearlyaseﬀectivelyasdirect
injection of HS or LPS [121]. Thus therapeutic measures
aimed at blocking elastase could reduce the production of
endogenous TLR4 activators. Indeed, pre-treatment with NE
inhibitor before induction of hepatic ischemia-reperfusion
injury ameliorated liver damage [168].HS fragmentsarealso
generated upon ECM oxidation by reactive oxygen species
(ROS). Extracellular superoxide dismutase (EC-SOD) is an
antioxidant enzyme that protects the lung from oxidant-
mediated inﬂammation. One way in which it does this is to
protect HS from oxidative fragmentation; bronchoalveolar
lavage ﬂuid from EC-SOD knockout mice after asbestos
exposure showed increased HS shedding from the lung
parenchyma [183]. An alternative strategy may be to alter
the balance of immune-silent intact ECM molecules versus
immune-stimulatory fragments either directly or indirectly.
SpeciﬁcoverexpressionofhighMWHAinthelunghasbeen
achieved using transgenic mice that constitutively express
HA synthase. These mice showed that improved survival
and decreased apoptosis during bleomycin induce lung
inﬂammation [145].
Finally, for DAMPs whose expression is speciﬁcally
upregulated during inﬂammation it may be possible to
manipulate this induction of expression. Indeed, knock-
down of versican expression in Lewis lung carcinoma cell
lines (LLC) ablated their tumorigenic capability, promoting
mouse survival and reduced metastasis, whilst overexpres-
sion of versican in LLC lines with low innate metastatic
potential increased lung metastasis [25].
Together these data indicate that endogenous TLR
activators signiﬁcantly contribute to driving inﬂammatory
disease in vivo and suggest that targeting this method of
TLR activation may potentially be of therapeutic value in
combating disease.
5. Conclusions and Perspectives:
TargetingDAMPsintheClinic?
Current strategies in clinical development for TLR blockade
include (1) global blockade of individual TLR function
using neutralizing antibodies, soluble TLR extracellular
domains (ECDs), natural antagonists, and small molecule
inhibitors, (2) inhibition of signalling pathways-activated
downstream of TLR stimulation using small molecules
to target MyD88/TRAF/IRAK complex formation, MAPK,
or IKK activity, or (3) using PAMP antagonists such as
LPS inhibitors. Some of these compounds have reached
phase II clinical trials and the results are currently awaited,
whilstothers,particularlythosetargetingcommonsignalling
pathwayssuchasMAPK,haveprovedtobeoflimitedeﬃcacy
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Suppressing DAMP activation of TLRs oﬀers a host of
new potential targets for treating inﬂammatory diseases that
may be viable alternatives to current approaches. Evidence
that blockade of these mediators can ameliorate disease
in human studies is beginning to emerge. Hyaluronate
improves pain and prostaglandin E (PGE) levels in patients
with RA [184], transfer of HSP-speciﬁc regulatory T cells
inhibits inﬂammation in animal models of arthritis and
exhibited promising results in preliminary clinical trials
[185], HMGB1 antibodies prevent the activation of cells
by serum from SLE patients [46], and the neutrophil
elastase inhibitor sivelestat improves the mortality rate of
patients with sepsis [186, 187]. By carefully choosing a
target unique to the response to tissue damage, and not
to pathogen mediated activation of the immune response,
this strategy may have the additional advantage of leaving
the host response to infection intact. Given the evidence
that supports the idea that distinct molecular machinery
is required for DAMP activation of TLRs, another strategy
would be to block co-receptors or accessory molecules
essential for DAMP activation. In addition a comparative
analysis of adaptors, kinases, and transcription factors
involved in signalling activated by DAMPs versus PAMPs
may highlight key diﬀerences that, if selectively targeted,
could lead to speciﬁc therapies engineered to silence danger
signals without compromising the host immune defence.
We have highlighted here the possible levels of inter-
vention in DAMP activation of TLR-mediated inﬂamma-
tion, namely, manipulating DAMP activation of TLRs or
controlling tissue level of DAMPs. Whilst these strategies
are eﬃcacious in preventing experimental disease, there is
also evidence that preconditioning with DAMPs can have
the same eﬀect. Administration of small doses of HMGB1
one hour prior to induction of hepatic reperfusion injury
protected from liver damage and reduced serum TNFα and
IL-6 levels via inhibition of TLR4 signalling [188, 189]a n d
lactoferrin can protect from lethal E.coli injection [190].
It is apparent that low tissue levels of DAMPs are
beneﬁcial during tissue repair to induce a resolvable,
physiological immune response. In contrast, high levels of
DAMPs are generated during chronic inﬂammation. We
propose a situation where a damage chain reaction occurs:
increasing levels of pro-inﬂammatory DAMPs create more
tissue damage which signiﬁcantly ampliﬁes the tissue levels
of DAMPs which go on to create yet more tissue damage
ad inﬁnitum. These tissue levels of DAMPs become harmful
and mediate a non-resolving perpetual inﬂammatory state
(Figure 4). Thus targeting DAMP-mediated activation of
TLRs may block this chronic inﬂammatory loop, although it
will be important to assess whether total blockade of DAMP
function will compromise tissue repair to any deleterious
extent.
In addition, in the destructive milieu that occurs during
inﬂammatory disease there are likely to be high levels
of many DAMPs. Working out which are keys to disease
pathogenesis may not be a trivial matter, and combinations
of inhibitors may be needed to successfully dampen down
endogenously driven inﬂammation. Alternatively, hierar-
chies may exist amongst DAMPs such as those that exist for
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Figure 4: The “damage chain reaction.” Harmful stimuli, including
pathogens, injury, heat, autoantigens, tumor, and necrotic cells,
cause tissue damage. Endogenous danger signals are generated and
induce a pro-inﬂammatory cascade by activating TLRs. In turn,
pro-inﬂammatory mediators are upregulated and trigger further
tissue damage leading to increasing DAMPs levels. Thus a vicious
cycle is sustained and may result in chronic inﬂammation and
autoimmunity.
inﬂammatory cytokines, for example, where TNFα induces
a cascade of cytokine synthesis. Indeed, low MW HA
induces β-defensin2 via TLR2 and 4 activation in murine
keratinocytes ex vivo and in vivo [191]. These DAMPs may
be key targets to prevent the induction of an autocrine
loop of inﬂammation. Unravelling potential hierarchies
amongst DAMPs represents a major challenge for future
investigations. These may be aided by approaches such as
microarray and deep sequencing technologies, as well as
proteomewide screening, to enable the comparison of the
global eﬀects of diﬀerent DAMPs on inﬂammatory gene
expression. Likewise, examining the stimuli that induce
DAMP expression or release upon tissue injury will be
important in establishing a “chain of command” of DAMP
action. In parallel, the development of validated reagents
and tools which serve to ablate the expression or function
of individual DAMPS will yield key information about
redundancy and co-dependency.
The threshold of DAMP(s) required to induce disease
may vary upon the duration and degree of host tissue
damage. However, current knowledge about the kinetics of
expression or release of DAMPs and their turnover during
diseaseprogressionislimited.Indeed,ononehand,validated
commercialassaysformeasuringvariousendogenousdanger
signals are often unavailable or prohibitively expensive. On
the other hand, access to patient specimens and pathological
data is in many cases restricted. Thus, the correlation
between degree of tissue damage and levels of DAMP(s)
is either unknown or limited to small sample size, often
representative of end stage of disease. The threshold of12 Mediators of Inﬂammation
DAMPs required to trigger chronic inﬂammation may also
depend on a variety of host genetic factors, including single-
nucleotide polymorphisms (SNPs), which can aﬀect how
humans respond to injury and develop disease. Examining
the role of DAMPs within the context of diﬀerent genetic
backgrounds will also be key to dissecting out their role
in inﬂammatory disease. The use of larger patient sample
sizes including diverse genetic populations and a beﬁtting
proportion of male and females will be vital. In addition,
the development of mouse strains with much greater DNA
diversity than strains traditionally employed [192]m a y
provide mice with combinations of diﬀerent traits that
more closely reﬂect the genomic variations of humans in
preclinical studies. We expect that the next few years will
provide a much more concrete picture of how DAMPs link
tissue damage to chronic inﬂammation as an increasing
number of tools become available.
Finally, a normal wound healing response does not typ-
ically lead to chronic inﬂammation. This is, in part, because
a number of mechanisms exist to negatively regulate TLR
activation. These include the release of soluble decoy TLR
receptors, intracellular inhibitory molecules such as IRAK-
M, SOCS1, Tam family kinases, and transmembrane regu-
lators such as SIGIRR (reviewed in [8, 193]). Viruses have
alsoevolvedmechanismstotargetadaptersinTLRsignalling:
A46R from vaccinia virus, which sequesters MyD88, Mal,
Trif, and Tram [194], and NS3/4A from hepatitis C virus,
which degrades Trif [195]. In addition, recently, microRNA,
miR-147, whose expression is induced upon stimulation of
multiple TLRs, was shown to attenuate TLR stimulation-
induced-inﬂammatory response in macrophages [196].
However, these pathways do not appear to discriminate
between distinct methods of TLR stimulation and act on
DAMP- and PAMP-mediated activation alike. Chen et al.
recently identiﬁed one way in which speciﬁc activation
of TLRs by DAMPs, but not PAMPs, may be inhibited
(reviewed in [197]). CD24, or heat stable antigen, is a GPI
anchored protein that binds to DAMPs such as HMGB1,
hsp70, and hsp90 in order to suppress their activation of
inﬂammatory signalling pathways. CD24 null mice exhibit
increased susceptibility to DAMP-, but not PAMP, induced
inﬂammation.ThisismediatedatleastinpartthroughCD24
association with Siglec-10/G causing activation of associated
phosphatases which are proposed to repress DAMP-initiated
signalling. Dysfunction of this pathway might contribute
to the etiology of autoimmune diseases and likewise may
oﬀer a means to selectively inhibit DAMP activity [198].
In addition, sTLR2 can blunt immune responses without
preventing microbial recognition: mice injected with Gram
positive bacteria together with sTLR2 exhibited reduced
inﬂammatory cytokine levels and cell migration but this
did not compromise their ability to clear live Gram-positive
bacteria-induced infection [199]. As such enhancing natu-
rally suppressive mechanisms may also be a viable strategy
for reducing inﬂammation.
Thus DAMPs appear to be a double-edged sword. While
being vital for tissue repair, they also play a role in the
pathogenesis of many inﬂammatory and autoimmune dis-
eases that feature aberrant TLR activation. In these diseases
harmful stimuli cause tissue damage; in an attempt of tissue
healing, inﬂammatory responses are initiated and generate
DAMPs that induce an autocrine loop of inﬂammation.
Understanding why the natural mechanisms that keep
DAMP-mediated inﬂammation in check fail in disease, as
well as dissecting out which mechanisms of TLR activation
and signalling are unique to DAMPs, may enlighten our
approach to engineering targeted and eﬃcacious therapies
designed to dampen inﬂammation.
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